Side effects include those of other statins, such as myalgias, abdominal pain, nausea. It also has a higher chance of giving more severe side effects related to myotoxicity (myopathy, myositis, rhabdomyolysis), and hepatotoxicity, than other statins. Due to these major side effects and their enhanced rate of occurance, Mevastatin is not given therapeutically.
Mevastatin or compactin is a cholesterol-lowering agent isolated from Penicillium citinium. It was the first discovered agent belonging to the class of cholesterol-lowering medications known as statins. During a search for antibiotic compounds produced by fungi in 1971, Akira Endo at Sankyo Co. (Japan) discovered a class of compounds that appeared to lower plasma cholesterol levels. Two years later, the research group isolated a compound structurally similar to hydroxymethylglutarate (HMG) that inhibited the incorporation of acetate. The compound was proposed to bind to the reductase enzyme and was named compactin. Mevastatin is a competitive inhibitor of HMG-Coenzyme A (HMG-CoA) reductase with a binding affinity 10,000 times greater than the HMG-CoA substrate itself. Mevastatin is a pro-drug that is activated by in vivo hydrolysis of the lactone ring. It has served as one of the lead compounds for the development of the synthetic compounds used today.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Acipimox | Acipimox may increase the myopathic rhabdomyolysis activities of Mevastatin. |
| Bezafibrate | Bezafibrate may increase the myopathic rhabdomyolysis activities of Mevastatin. |
| Ciprofibrate | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofibrate is combined with Mevastatin. |
| Colchicine | Colchicine may increase the myopathic rhabdomyolysis activities of Mevastatin. |
| Daptomycin | The risk or severity of myopathy can be increased when Mevastatin is combined with Daptomycin. |
| Gemfibrozil | The risk or severity of rhabdomyolysis, myoglobinuria, and elevated creatine kinase (CPK) can be increased when Gemfibrozil is combined with Mevastatin. |
| Niacin | The risk or severity of myopathy and rhabdomyolysis can be increased when Niacin is combined with Mevastatin. |
| Pazopanib | Mevastatin may increase the hepatotoxic activities of Pazopanib. |
| Raltegravir | The risk or severity of myopathy and rhabdomyolysis can be increased when Raltegravir is combined with Mevastatin. |
| Trabectedin | The risk or severity of myopathy and rhabdomyolysis can be increased when Mevastatin is combined with Trabectedin. |
| Amiodarone | The metabolism of Mevastatin can be increased when combined with Amiodarone. |
| Danazol | The serum concentration of Mevastatin can be increased when it is combined with Danazol. |
| Colestipol | Colestipol can cause a decrease in the absorption of Mevastatin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sevelamer | Sevelamer can cause a decrease in the absorption of Mevastatin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Colesevelam | Colesevelam can cause a decrease in the absorption of Mevastatin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cholestyramine | Cholestyramine can cause a decrease in the absorption of Mevastatin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Fusidic acid | The risk or severity of rhabdomyolysis can be increased when Fusidic acid is combined with Mevastatin. |
| Clofibrate | The risk or severity of myopathy and rhabdomyolysis can be increased when Clofibrate is combined with Mevastatin. |
| Fenofibrate | The risk or severity of myopathy and rhabdomyolysis can be increased when Fenofibrate is combined with Mevastatin. |
| Etofibrate | The risk or severity of myopathy and rhabdomyolysis can be increased when Etofibrate is combined with Mevastatin. |
| Simfibrate | The risk or severity of myopathy and rhabdomyolysis can be increased when Simfibrate is combined with Mevastatin. |
| Ronifibrate | The risk or severity of myopathy and rhabdomyolysis can be increased when Ronifibrate is combined with Mevastatin. |
| Aluminium clofibrate | The risk or severity of myopathy and rhabdomyolysis can be increased when Aluminium clofibrate is combined with Mevastatin. |
| Clofibride | The risk or severity of myopathy and rhabdomyolysis can be increased when Clofibride is combined with Mevastatin. |
| Fenofibric acid | The risk or severity of myopathy and rhabdomyolysis can be increased when Fenofibric acid is combined with Mevastatin. |
| Lanthanum carbonate | The absorption of Mevastatin can be decreased when combined with Lanthanum carbonate. |
| Clarithromycin | The metabolism of Mevastatin can be decreased when combined with Clarithromycin. |
| Ubidecarenone | The risk or severity of myopathy and rhabdomyolysis can be decreased when Ubidecarenone is combined with Mevastatin. |
| Erlotinib | The metabolism of Mevastatin can be decreased when combined with Erlotinib. |
| Leuprolide | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Mevastatin. |
| Somatotropin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Mevastatin. |
| Infliximab | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Mevastatin. |
| Cyclosporine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Mevastatin. |
| Pravastatin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pravastatin is combined with Mevastatin. |
| Baclofen | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Baclofen is combined with Mevastatin. |
| Sildenafil | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Sildenafil is combined with Mevastatin. |
| Indinavir | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Indinavir is combined with Mevastatin. |
| Lovastatin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lovastatin is combined with Mevastatin. |
| Cladribine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Mevastatin. |
| Phenytoin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Phenytoin is combined with Mevastatin. |
| Pamidronic acid | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Mevastatin. |
| Mefloquine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Mefloquine is combined with Mevastatin. |
| Tacrine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrine is combined with Mevastatin. |
| Carbimazole | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Carbimazole is combined with Mevastatin. |
| Cerivastatin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cerivastatin is combined with Mevastatin. |
| Trimethoprim | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Mevastatin. |
| Betamethasone | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Betamethasone is combined with Mevastatin. |
| Montelukast | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Montelukast is combined with Mevastatin. |
| Zidovudine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Zidovudine is combined with Mevastatin. |
| Cimetidine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cimetidine is combined with Mevastatin. |
| Ritonavir | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ritonavir is combined with Mevastatin. |
| Lercanidipine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lercanidipine is combined with Mevastatin. |
| Ciprofloxacin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Mevastatin. |
| Vincristine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Vincristine is combined with Mevastatin. |
| Propylthiouracil | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Mevastatin. |
| Methotrexate | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Methotrexate is combined with Mevastatin. |
| Enalapril | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Enalapril is combined with Mevastatin. |
| Nizatidine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nizatidine is combined with Mevastatin. |
| Ivermectin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ivermectin is combined with Mevastatin. |
| Chloroquine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Chloroquine is combined with Mevastatin. |
| Triamcinolone | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Triamcinolone is combined with Mevastatin. |
| Alendronic acid | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Mevastatin. |
| Simvastatin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Simvastatin is combined with Mevastatin. |
| Stavudine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Stavudine is combined with Mevastatin. |
| Nafarelin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nafarelin is combined with Mevastatin. |
| Amphotericin B | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Mevastatin. |
| Mycophenolate mofetil | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Mycophenolate mofetil is combined with Mevastatin. |
| Lamivudine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lamivudine is combined with Mevastatin. |
| Ibandronate | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Mevastatin. |
| Propofol | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propofol is combined with Mevastatin. |
| Terbinafine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Terbinafine is combined with Mevastatin. |
| Penicillamine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Penicillamine is combined with Mevastatin. |
| Ranitidine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ranitidine is combined with Mevastatin. |
| Tacrolimus | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrolimus is combined with Mevastatin. |
| Eprosartan | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Eprosartan is combined with Mevastatin. |
| Risedronic acid | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Risedronic acid is combined with Mevastatin. |
| Bumetanide | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Bumetanide is combined with Mevastatin. |
| Triazolam | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Triazolam is combined with Mevastatin. |
| Ethanol | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ethanol is combined with Mevastatin. |
| Salmeterol | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Salmeterol is combined with Mevastatin. |
| Isoniazid | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Isoniazid is combined with Mevastatin. |
| Methyldopa | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Methyldopa is combined with Mevastatin. |
| Isotretinoin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Isotretinoin is combined with Mevastatin. |
| Cytarabine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Mevastatin. |
| Ganciclovir | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ganciclovir is combined with Mevastatin. |
| Letrozole | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Letrozole is combined with Mevastatin. |
| Sulfamethoxazole | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Sulfamethoxazole is combined with Mevastatin. |
| Minocycline | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Minocycline is combined with Mevastatin. |
| Procainamide | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Procainamide is combined with Mevastatin. |
| Norfloxacin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Norfloxacin is combined with Mevastatin. |
| Atorvastatin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Atorvastatin is combined with Mevastatin. |
| Fluvastatin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Fluvastatin is combined with Mevastatin. |
| Rosuvastatin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Rosuvastatin is combined with Mevastatin. |
| Ofloxacin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ofloxacin is combined with Mevastatin. |
| Procarbazine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Procarbazine is combined with Mevastatin. |
| Captopril | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Captopril is combined with Mevastatin. |
| Paclitaxel | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Paclitaxel is combined with Mevastatin. |
| Saquinavir | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Saquinavir is combined with Mevastatin. |
| Metoclopramide | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Metoclopramide is combined with Mevastatin. |
| Dexamethasone | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Dexamethasone is combined with Mevastatin. |